Advertisement
Screener

BRISTOL-MYERS SQUIBB COMPANY (BMY) Amortization

2.8 / 5 stars · 68/120 Roast Me

BRISTOL-MYERS SQUIBB COMPANY Amortization

BRISTOL-MYERS SQUIBB COMPANY (BMY) reported Amortization of $203.00 million for the 6-month period ending 2012-06-30, per its 10-Q filed 2012-07-25.

Discontinued › Cash Flow › Operating Activities

us-gaap:AdjustmentForAmortization · last filed 2012-07-25

  • BRISTOL-MYERS SQUIBB COMPANY amortization for the quarter ending 2012-06-30 was $102.00M, a 7.37% increase year-over-year.
  • BRISTOL-MYERS SQUIBB COMPANY amortization for the quarter ending 2012-03-31 was $101.00M, a 38.36% increase year-over-year.
  • BRISTOL-MYERS SQUIBB COMPANY amortization for the quarter ending 2011-12-31 was $92.00M, a 26.03% increase year-over-year.
  • BRISTOL-MYERS SQUIBB COMPANY amortization for the quarter ending 2011-09-30 was $93.00M, a 40.91% increase year-over-year.
  • BRISTOL-MYERS SQUIBB COMPANY amortization for fiscal 2011 was $353.00M, a 30.26% increase from fiscal 2010.
  • BRISTOL-MYERS SQUIBB COMPANY amortization for fiscal 2010 was $271.00M, a 13.87% increase from fiscal 2009.
  • BRISTOL-MYERS SQUIBB COMPANY amortization for fiscal 2009 was $238.00M, a 6.30% decline from fiscal 2008.
  • BRISTOL-MYERS SQUIBB COMPANY amortization for fiscal 2008 was $254.00M, a 27.43% decline from fiscal 2007.
Period endAmortization 3 monthAmortization 6 monthAmortization 6 month as first filedAmortization 9 monthAmortization 9 month as first filedAmortization 12 month
2012-06-30$102.00M
derived: 10-Q 6 month − 10-Q 3 month · filed 2012-07-25
$203.00M
10-Q · filed 2012-07-25
$295.00M
derived: sum of 3 quarters · filed 2012-07-25
$388.00M
derived: sum of 4 quarters · filed 2012-07-25
2012-03-31$101.00M
10-Q · filed 2012-04-26
$193.00M
derived: sum of 2 quarters · filed 2012-04-26
$286.00M
derived: sum of 3 quarters · filed 2012-04-26
$381.00M
derived: sum of 4 quarters · filed 2012-07-25
2011-12-31$92.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-17
$185.00M
derived: sum of 2 quarters · filed 2012-02-17
$280.00M
derived: sum of 3 quarters · filed 2012-07-25
$353.00M
10-K · filed 2012-02-17
2011-09-30$93.00M
derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-27
$188.00M
derived: sum of 2 quarters · filed 2012-07-25
$261.00M
10-Q · filed 2011-10-27
$334.00M
derived: sum of 4 quarters · filed 2012-07-25
2011-06-30$95.00M
derived: 10-Q 6 month − 10-Q 3 month · filed 2012-07-25
$168.00M
10-Q · filed 2012-07-25
$241.00M
derived: sum of 3 quarters · filed 2012-07-25
$307.00M
derived: sum of 4 quarters · filed 2012-07-25
2011-03-31$73.00M
10-Q · filed 2012-04-26
$146.00M
derived: sum of 2 quarters · filed 2012-04-26
$212.00M
derived: sum of 3 quarters · filed 2012-04-26
$279.00M
derived: sum of 4 quarters · filed 2012-04-26
2010-12-31$73.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-17
$139.00M
derived: sum of 2 quarters · filed 2012-02-17
$206.00M
derived: sum of 3 quarters · filed 2012-02-17
$271.00M
10-K · filed 2012-02-17
2010-09-30$66.00M
derived: 10-Q 9 month − 10-Q 6 month · filed 2011-10-27
$133.00M
derived: sum of 2 quarters · filed 2011-10-27
$198.00M
10-Q · filed 2011-10-27
$259.00M
derived: sum of 4 quarters · filed 2012-02-17
2010-06-30$67.00M
derived: 10-Q 6 month − 10-Q 3 month · filed 2011-07-28
$132.00M
10-Q · filed 2011-07-28
$193.00M
derived: sum of 3 quarters · filed 2012-02-17
$257.00M
derived: sum of 4 quarters · filed 2012-02-17
2010-03-31$65.00M
10-Q · filed 2011-04-28
$126.00M
derived: sum of 2 quarters · filed 2012-02-17
$190.00M
derived: sum of 3 quarters · filed 2012-02-17
$246.00M
derived: sum of 4 quarters · filed 2012-02-17
2009-12-31$61.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-17
$125.00M
derived: sum of 2 quarters · filed 2012-02-17
$181.00M
derived: sum of 3 quarters · filed 2012-02-17
$238.00M
10-K · filed 2012-02-17
2009-09-30$64.00M
derived: 10-Q 9 month − 10-Q 6 month · filed 2010-10-26
$120.00M
derived: sum of 2 quarters · filed 2010-10-26
$177.00M
10-Q · filed 2010-10-26
$160.00M
10-Q · filed 2009-10-22
$244.00M
derived: sum of 4 quarters · filed 2011-02-18
2009-06-30$56.00M
derived: 10-Q 6 month − 10-Q 3 month · filed 2010-07-22
$113.00M
10-Q · filed 2010-07-22
$101.00M
10-Q · filed 2009-07-23
$180.00M
derived: sum of 3 quarters · filed 2011-02-18
$241.00M
derived: sum of 4 quarters · filed 2011-02-18
2009-03-31$57.00M
10-Q · filed 2010-04-29
$124.00M
derived: sum of 2 quarters · filed 2011-02-18
$185.00M
derived: sum of 3 quarters · filed 2011-02-18
2008-12-31$67.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-18
$128.00M
derived: sum of 2 quarters · filed 2011-02-18
$254.00M
10-K · filed 2011-02-18
2008-09-30$61.00M
derived: 10-Q 9 month − 10-Q 6 month · filed 2009-10-22
$187.00M
10-Q · filed 2009-10-22
2008-06-30$126.00M
10-Q · filed 2009-07-23
2007-12-31$350.00M
10-K · filed 2010-02-19

Similar stocks

Stock NameCountryMarket CapPE Ratio
VERTEX PHARMACEUTICALS INC / MA (VRTX)United States$132.481B28.56
PFIZER INC (PFE)United States$162.042B31.94
ABBOTT LABORATORIES (ABT)United States$176.045B28.47
REGENERON PHARMACEUTICALS, INC. (REGN)United States$74.751B21.53
ALNYLAM PHARMACEUTICALS, INC. (ALNY)United States$33.420B54.94
Zoetis Inc. (ZTS)United States$29.045B11.38
INSMED Inc (INSM)United States$26.566B-26.60
Roivant Sciences Ltd. (ROIV)$26.105B-96.08
Royalty Pharma plc (RPRX)United States$22.628B
UNITED THERAPEUTICS Corp (UTHR)United States$20.249B17.64